TWIN STAR TDS, LLC — Department of Health and Human Services SBIR Phase I: 102
TWIN STAR TDS, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $339,842
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 102
- Solicitation
- PA16-019
- NAICS
- —
- Place of performance
- KY
- Period
- 2015-05-14 → 2017-10-31
Description
DESCRIPTION provided by applicant The objective of this proposal is to demonstrate the feasibility of an innovative injection device proposed product to improve upon intratumoral delivery of liver therapeutics as compared to standard injection needles currently used Hepatocelluar carcinoma HCC will become an increasing burden on economic resources in the coming years as the prevalence of cirrhosis due to multiple disease processes in the general population increases Transplant and surgical treatment are well established and have provided satisfactory overall survival for eligible patients however only a small minority of HCC patients are eligible for these therapies Therefore considerable efforts have been directed toward developing alternative minimally invasive treatments HCC therapeutic delivery by direct injection has the potential to significantly reduce the expense and morbidity of current therapeutics or those in development Though direct injection is a seemingly straightforward approach to the problem limited ability to inject tumors greater than cm in diameter and uneven distribution of the therapeutic after injection are significant drawbacks to direct injectin In contrast to conventional injection needles the proposed injection device is porous along the entire length of the targeted anatomy therefore the surface area of tissue in contact with infusate is considerably increased Hypothesis Improved infusate delivery will lead to a larger area and more uniform distribution of infusate within the tumor tissue and lend itself to enhanced therapeutic direct intratumoral injection protocols for various chemoablative and anti neoplastic infusates Preliminary Data We have demonstrated that porous injection devices have significantly improved in vivo distribution of ethanol within normal canine prostates and other studies have demonstrated the unique performance benefits of applicantandapos s porous injection device Specific Aim This project entails preclinical testing of the porous injection device for eventual application to human patients with intrahepatic tumors Aim Demonstrate that the porous injection device provides broader distribution of an infusate compared to a standard needle Task Transfer of VX Cells and growth of tumor in rabbit for tumor implant tissue Task Determine the preferred flow rate for infusate into the VX tumor in rabbit liver Task Comparison of concentration and distribution of infusate components after infusion into VX tumor with porous device and standard needle Milestone The porous injection device will show greater distribution as compared to needle injection PUBLIC HEALTH RELEVANCE Effective drug delivery of therapeutic agents directly into avascular regions of solid tumors is challenging with current clinical methodologies The Applicants have developed novel porous hollow fiber catheters which have the potential to demonstrate more uniform and better distribution of an infusate into solid tumor tissue than standard of care needles In this project animal studies will be conducted to compare the PHFC to standard needle for infusate delivery into a liver cancer animal model